by John Cook on Aug 14, 2026 at 6:33 am August 14, 2026 at 6:33 am

InduPro, a 4-year-old biotech startup with operations in Seattle and Cambridge, Mass., this week announced $77 million in series B funding as it begins a Phase 1 clinical trial of its lead cancer drug candidate.

The company said that the first patient has been dosed in the trial of IDP-001, an experimental antibody-drug conjugate designed to target cancer cells through a combination of two proteins on their surface.

The early-stage trial is enrolling adults with advanced or metastatic non-small cell lung cancer and other solid tumors whose disease has progressed following…

Read the full article at GEEKWIRE.COM